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Abstract
Background: Understanding how androgen receptor (AR) function is modulated by exposure to steroids, growth factors or
small molecules can have important mechanistic implications for AR-related disease therapies (e.g., prostate cancer,
androgen insensitivity syndrome, AIS), and in the analysis of environmental endocrine disruptors.
Methodology/Principal Findings: We report the development of a high throughput (HT) image-based assay that quantifies
AR subcellular and subnuclear distribution, and transcriptional reporter gene activity on a cell-by-cell basis. Furthermore,
simultaneous analysis of DNA content allowed determination of cell cycle position and permitted the analysis of cell cycle
dependent changes in AR function in unsynchronized cell populations. Assay quality for EC50 coefficients of variation were
5–24%, with Z’ values reaching 0.91. This was achieved by the selective analysis of cells expressing physiological levels of AR,
important because minor over-expression resulted in elevated nuclear speckling and decreased transcriptional reporter
gene activity. A small screen of AR-binding ligands, including known agonists, antagonists, and endocrine disruptors,
demonstrated that nuclear translocation and nuclear ‘‘speckling’’ were linked with transcriptional output, and specific
ligands were noted to differentially affect measurements for wild type versus mutant AR, suggesting differing mechanisms
of action. HT imaging of patient-derived AIS mutations demonstrated a proof-of-principle personalized medicine approach
to rapidly identify ligands capable of restoring multiple AR functions.
Conclusions/Significance: HT imaging-based multiplex screening will provide a rapid, systems-level analysis of compounds/
RNAi that may differentially affect wild type AR or clinically relevant AR mutations.
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Introduction
The androgen receptor (AR), a member of the nuclear receptor
superfamily, functions to regulate gene expression in response to
androgens such as testosterone (T) and dihydrotestosterone
(DHT). Several cell-based imaging models have been generated
in recent years to study AR action, enabling researchers to
correlate transcriptional competence of AR with some obligatory
intracellular steps visible by fluorescence microscopy. These steps
fit within the classical model of AR function: in response to
ligands, AR sheds heat shock proteins, forms dimers, and
translocates into the nucleus [1–3]. Upon entering the nucleus,
AR then organizes into thousands of discrete but unstable foci
(referred to as the hyperspeckled pattern), interacts with
coregulators and members of the general transcriptional appara-
tus, and regulates gene expression by interacting with androgen
response elements associated with androgen-regulated genes. The
microscopic model of antagonist-treated-AR has similarities, such
as induction of nuclear translocation, and differences, including a
diminished hyperspeckled pattern and repressed transcription
function [3].
AR signaling leads to differentiation of the male sexual
phenotype, and maturation of the secondary sex characteristics,
as well to maintenance of male libido, muscle mass and bone
density. Disruption of this signaling through inactivating mutations
of AR can lead to androgen insensitivity syndromes (AIS), in which
genotypic males are affected by a spectrum of developmental
abnormalities of the genital apparatus and of the secondary sexual
characteristics [4,5]. In addition to its role in AIS, AR is important
in prostate cell proliferation, differentiation and survival, and plays
at least a permissive role in development of prostate cancer [6].
Current therapy for advanced prostate cancer targets AR through
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3605the use of LHRH agonists and/or anti-androgens such as
hydroxyflutamide or bicalutamide (Casodex). These drugs work
by inhibiting androgen synthesis, or by preventing endogenous
androgens from activating AR, respectively. While these treat-
ments are initially successful, patients will eventually relapse in 18–
24 months and present with androgen depletion-independent
(ADI) disease, for which there is no effective cure; consequently,
ADI results in approximately 30,000 deaths per year in the United
States [7]. The molecular basis of transition to ADI is still
incompletely characterized, however several androgen receptor-
based hypotheses have been formulated [8], and they share the
common denominator that AR acquires the ability to signal even
in the androgen-depleted or AR-inhibited environment [9]. Some
of the AR-based hypotheses to explain the development of ADI
disease include development of activating AR mutations [10], AR
activation by testosterone and dihydrotestosterone, which can be
present in recurrent prostate cancer tissue at levels sufficient to
stimulate AR [11], AR activation by a pool of ligands generated
intraprostatically by increased expression of genes regulating
androgen metabolism [12], or even AR activation by anti-
androgens [13].
Some AR functions can now be investigated using automated
single cell microscopy [3,14]. This novel technology can be used to
investigate unanswered questions related to AR physiopathology
and to facilitate novel approaches to drug discovery. For instance,
there is the need to examine at the single cell level how AR
function is affected by various compounds, including traditional
AR agonists and antagonists, precursors of testosterone, steroidal
and non-steroidal substances known to bind AR with high or low
affinity, and how these ligand receptor interactions are affected by
AR mutations found in AIS and prostate cancer. In addition, due
to the fact that AR plays a major role in the embryologic
development of the male sexual phenotype and in spermatogen-
esis, there exist concerns on whether exposure to environmental
compounds that disrupt normal endocrine pathways may affect
AR-regulated functions [15]. Inasmuch that endocrine disruptors
are increasingly being identified in the environment at bioactive
levels and we do not know to what degree they affect AR function,
there is the need to thoroughly study them at a single cell, system
biology level to understand their mechanism of action.
Regarding drug discovery programs to identify the next
generation of AR agonists or antagonists, a number of cell-based
assays have been developed in the past, and most are based on use of
a luciferase reporter gene. The reporter gene is placed under control
of an AR-promoter or, in composite systems using Gal4-AR fusions,
a UAS- promoter, either transiently or stably transfected into a
selected cell lines. There are several limitations to this approach.
First, the results are intrinsically based on cumulative data derived
from thousands/millions of cells that certainly vary in terms of cell
cycle and/or AR expression level (either endogenous or transiently/
stably introduced). These are both important shortcomings, as
changesintheamountofexpressionofatranscriptionfactoraffectits
intracellular mobility [3], ability to interact with members of the
transcriptionalapparatusandtotranscribetargetgenes[16],andcell
cycle dependent sensitivity to AR functions have been suggested (see
below; [17]). Second, luciferase assays provide single read-outs,
yielding information only on the transcriptional reporter gene
activity of AR, and are unable to contribute information on how AR
cellulardistribution,subnuclearorganizationandmobility,promoter
occupancy and chromatin modeling are affected by various
compounds. A single cell-based multiplex assay would have the
ability to overcome some of these shortcomings, and more directly
provide information on the mechanism of action of novel AR
agonists or antagonists.
The importance of analyzing receptor activity at the single cell
level is highlighted by the role of cell cycle in nuclear receptor
transcriptional reporter gene activity. Early studies of the
glucocorticoid receptor indicated reduced receptor activity in G2
[18]. A more recent study examining PR in T47D cells found
highest PR activity in S phase. This activity was associated with
increased nuclear localization of the receptor and elevated
interaction with the nuclear receptor coactivators SRC-1 and
SRC-3 [17]. For AR, earlier studies have indicated that AR has
reduced activity in cells blocked in late G1/S phase compared to
G0 or S-phase [19]. Few of these studies have examined the
mechanisms behind the altered activity, and all have relied upon
an external agent to enrich cell populations in a particular phase of
the cell cycle. A single cell assay using selected markers would
provide the ability to examine the effects of cell cycle on the basic
mechanism of AR signaling without resorting to toxic inhibitors
that can, at best, only partially synchronize cells.
Here, we report the development and utilization of a novel high
throughput image-based transcriptional assay to study multiple
aspects of AR intracellular biology at the single cell level. The
assay is based upon image acquisition using robotic fluorescent
microscopy and automated image analysis, generally referred to as
high content screening (HCS) [20]. We have expanded upon our
previous HCS efforts by using androgen-responsive HeLa cell lines
that stably express either wild type or mutant AR fused to a green
fluorescent protein in combination with a probasin promoter-
based transcriptional reporter gene. This allows us to simulta-
neously quantify changes in AR nuclear translocation, nuclear
patterning, and transcriptional reporter gene activity in response
to compounds and AR mutations. Incorporation of EdU, a BrdU-
like marker for newly synthesized DNA also allows for the cell
cycle analyses in unsynchronized cell populations. We demon-
strate responses to a small panel of ligands and examine the
importance of AR expression level, the link between AR nuclear
patterning and transcriptional reporter gene activity, the relation-
ship between observed responses and cell cycle, and the functional
impact of the LNCaP T877A and AIS F764L mutations.
Results
Assay System
To examine how wild-type and mutant ARs (expressed at
physiologically relevant levels) respond to various experimental
manipulations, HeLa cell lines were generated that stably express
either wild type (GFP-AR), mutant GFP-ART877A (LNCaP
mutation; [13]), or GFP-ARF764L (AIS mutation; [21]) under
control of the CMV promoter. The T877A and F764L mutations
were selected due to known altered ligand responses [13].
Generated cell lines were characterized at the population level
by western blot analysis which indicated that HeLa GFP-AR,
HeLa GFP-AR T877A, and HeLa GFP-AR F764L expressed AR
of the expected size and at levels approximately 1.1-, 2.1, and 0.8-
fold of that found in LNCaP cell pools (Fig. 1A). Furthermore,
microarray-based RNA expression analysis demonstrated that
GFP-AR regulates (activation or repression) known endogenous
AR-responsive genes in response to ligand, indicating the cellular
machinery of HeLa readily supports AR transcription function
(Supplementary Table S1).
To further characterize the cell lines, we analyzed them at the
single cell level using fluorescence microscopy, and in each line,
.90% of the cells were GFP positive. In the absence of ligand,
GFP-AR was diffusely distributed cell-wide (Fig. 1B); GFP-AR
T877A and GFP-AR F764L were predominantly located in the
cytoplasm (Fig. 1C and 1D) in .95% of cells. Upon addition of
HTM Analysis of AR Functions
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95–97% had a majority of the signal in the nucleus (Fig. 1B–D).
Despite single cell cloning, expression between single HeLa cells
was heterogeneous and varied up to 12-fold. Therefore, we used
immunofluorescence to determine the relative AR expression level
in both stably transfected HeLa and LNCaP cells (Fig. 2A–D) to
define a sub-population of HeLa expressing AR at levels similar to
LNCaP (Fig. 2E). In subsequent analyses, only this refined,
homogenous subpopulation of HeLa cells were analyzed to limit
potential over-expression artifacts [3,16].
To allow visualization of AR regulated transcriptional reporter
gene activity, the HeLa cell lines were transiently transfected with
the pARR2PB-dsRED2skl reporter construct, based on the AR-
responsive composite probasin promoter (Fig. 3A), and then
incubated for 18 hours with a 10-point titration (10
25 to 10
214 M)
of the compounds of interest. The dsRED2skl gene encodes a red
Figure 1. HeLa GFP-AR cell lines expressing wild type and mutant AR able to translocate into nucleus in response to agonist. A.
Western blot analysis comparing HeLa (1), LNCaP (2), HeLa GFP-AR (3), HeLa GFP-AR T877A (4), and HeLa GFP-AR F764L (5) androgen receptor
expression. Equal total protein levels were loaded for all cell abstracts and confirmed with b-actin control. B, C, and D. Deconvolution images of
HeLa cell lines expressing stably integrated GFP-AR, GFP- AR T877A (LNCaP, ligand binding domain mutation), and GFP- AR T877A (AIS associated
mutation, ligand binding domain mutation), shown without (top) and with 10 nM or 100 nM R1881 (bottom). The LBD mutation in GFP-AR T877A or
GFP-F764L does not affect the ability to translocate into the nucleus.
doi:10.1371/journal.pone.0003605.g001
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improves detection due to concentrating dsRED2skl in the small
cytoplasmic organelles. When examining potential anti-androgen-
ic activity, test compounds were titred against 10 nM R1881, a
minimal dose found to be sufficient to generate a response in all
key measurements. Cells were imaged using an automated
microscope with a 406/0.90 NA objective. For each field, three
images were captured: DAPI (nuclei, blue), GFP (AR, green), and
Figure 2. HTM analysis allows selection of cells expressing physiologically relevant levels of GFP-AR. A and B. Representative images
of LNCaP cells (A) and HeLa cells stably transfected with GFP-AR (B) were immunolabeled and imaged to determine the GFP-AR signal that
corresponds to endogenous LNCaP AR expression levels. Exposure levels for the GFP (left) and anti-AR labeling (right) is identical for both cell types.
C. Image analysis was performed on the LNCaP antibody images to quantify the total anti-AR labeling per cell, derived from the standard 10610 field
of cells, containing .500 cells. The dashed lines indicate the 10% and 90% percentile of the population. D. Similar image analysis was performed on
the HeLa GFP-AR antibody images to quantify the total anti-AR labeling per cell. The dashed lines indicate the 10%–90% expression range found in
the LNCaP cell line. These cut-offs were empirically determined to remove the outliers, either barely-detectable GFP, or grossly over-expressing cells.
As can be seen in the histogram from the ,500 cell quantitation, removing the very heterogenous top 10%, or the more homogeneous bottom 10%,
only eliminates the extremes, which can have an untoward influence on the bulk of the population. E. HeLa GFP-AR cells with AR expression within
this range were selected and total GFP intensity per cell was determined and plotted. GFP expression corresponding to the 10% and 90% percentile
in this population were determined (dashed lines) and used as lower and upper limits of GFP-AR expression in all subsequent experiments. This
analysis enables the selection of HeLa GFP-AR cells with AR expression levels similar to that endogenously expressed in LNCaP cell line.
doi:10.1371/journal.pone.0003605.g002
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Pipeline Pilot (Accelrys) image analysis software was used to
identify individual cells in each image. For each cell, the DAPI
channel (Fig. 3B) was used to identify the nucleus, and the
remaining field was computationally segmented to determine the
cytoplasmic compartment for each cell (Fig. 3B–C). These masks
were then applied to the green and red images to determine
cellular distribution of GFP-AR and transcriptional reporter gene
activity (Fig. 3D–E). Cell populations were then sorted to remove
nuclei clusters (bi- or multinucleate), abnormal nuclear shape and/
Figure 3. Multiple6assay automated image analysis. A. The probasin proximal promoter element containing two AR binding sites duplicated
and fused to a peroxisomes-targeted dsRED2skl protein reporter. B. Raw gray-scale image of HeLa cell nuclei stained with DAPI. White box indicates
view used in rest of figure. C. Binary nuclear mask generated by non-linear least squares image filter and image field segmentation based on nuclear
centroids and veronoi tessellation. This tessellation in combination with a user defined radius rule defines cytoplasmic compartment of each cell. D.
Virtual pseudo color well image generated after GFP-AR data extraction. E. AR transcriptional reporter gene activity at single cell level determined by
dsRED2skl image data extraction. All screen captures directly from Cytoshop with various features toggled on/off.
doi:10.1371/journal.pone.0003605.g003
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expression levels as defined above. To analyze the GFP-AR
subcellular trafficking and transcription results, three key features
were determined for each cell: 1) degree of nuclear translocation
(fraction of GFP signal localized in nucleus, FLIN):
FLIN~
P
GFP IntensityNucleus P
GFP IntensityCell
2) amount of nuclear hyperspeckling (nuclear variation of GFP
signal intensity, NVAR):
NVAR~
P
X{c ðÞ
2
N
(where X is each nuclear GFP pixel intensity, c is the average GFP
pixel intensity, and N is the number of pixels in the nucleus) and,
3) transcriptional reporter gene activity (total amount of
correlated channel 2/dsRED2skl signal, CORR2):
CORR2~
X
dsRED IntensityCell
All measurements are then normalized to those observed in
untreated and treated (100 nM R1881) GFP-AR. The ability to
measure the hyperspeckled patterning is important because it is
thought to represent the formation of transient protein complexes
by the receptor as it scans the DNA for androgen response
elements [22,23]. The ability of the IC-100 to rapidly focus using a
high NA 406 objective was particularly important for these
measurements.
Assay Quality and Repeatability
To determine the repeatability of the minimum and maximum
responses (dynamic range) of the assay, we randomly selected and
measured 50 cells treated with either the positive control (100 nM
R1881, 2 hrs) or the negative control (no ligand). We then
calculated the mean, standard deviation (SD), and coefficient of
variation (CV) for each measurement for all cells in each of the two
wells (Supplementary Table S2). This analysis was repeated 5
times for 5 other pairs of wells. The mean values for each of the
three parameters (FLIN, NVAR, and CORR2) did not vary by
more than 5% demonstrating that each of these measures is
repeatable.
To determine overall assay repeatability, three replicate plates
were prepared containing replicates of a 10-point R1881 titration
curve with concentrations ranging from 1000 nM to 0.01 nM, and
a control well with no ligand treatment. Each plate was imaged
once and all measurements were determined (Supplementary Fig.
S1A–C). The Z’ values, a dimensionless measurement of assay
quality based on sample means and their standard deviations, were
calculated [24,25]. A Z’ value of 1 is the theoretical ‘‘perfect’’ assay
and values between 0.2 and 0.6 are typical for cell based assays
[25]. For the replicate sets, the maximum calculated Z’ values
were 0.76, 0.91, and 0.59 for FLIN, NVAR, and CORR2 and
ranged between 0.46 and 0.91 depending on groups and
measurements being compared (Supplementary Table S3).
Variability in EC50 values calculated upon curve fitting using
SigmaPlot software ranged between 5 and 24% (Supplementary
Table S4). Reports of EC50 variability in traditional transcrip-
tional reporter gene-based assays have been reported to range
between 22 and 57% [26], indicating our HTM-based data is
improved in this regard. Since total assay throughput is limited by
image acquisition speed, we utilized a derivation of Devore [27] to
estimate the minimum number of cell measurements needed per
well to achieve significance (Methods). In general, the number of
frames per well was set to capture twice the minimum number of
cells predicted as necessary to account for any well-to-well
differences in the actual number of cells analyzed.
AR Nuclear Translocation and Hyperspeckling are Distinct
Responses
To demonstrate the ability to use the assay as a screening tool,
known AR agonists that have similar high affinity for AR [28]
were tested over a wide range of concentrations, including R1881,
mibolerone, and DHT. Whereas DHT can rapidly be metabolized
[29], the synthetic androgens R1881 and mibolerone are relatively
stable [30]. All three compounds induced GFP-AR nuclear
translocation, nuclear hyperspeckling and dsRED2skl transcrip-
tional reporter gene activity in a dose-dependent manner (Fig. 4
and Supplementary Table S6). Using R1881, the calculated EC50
concentration for nuclear translocation, nuclear hyperspeckling,
and transcriptional reporter gene activity were 0.9660.03 nM,
30.764.5 nM, and 28.264.2 nM, respectively. The AR agonists
DHT and mibolerone demonstrated similar effects as compared to
R1881, differing only in that DHT was approximately 10-fold less
efficient in inducing nuclear translocation. It is interesting to note
that the EC50 for hyperspeckling and transcriptional reporter gene
activity were both ,30-fold higher than that of nuclear
translocation, indicating that AR translocation and hyperspeck-
ling/transcriptional reporter gene activity are distinct biological
steps and that highly quantitative data can be culled from this
multiplex imaging-based approach.
To determine the effects of the GFP fusion on AR function, we
directlycomparedthe responses of GFP-ARand untaggedARwhen
transiently-transfected into HeLa cells along with the pARR2PB-
dsRED2skl reporter gene construct and exposed to various doses of
DHT. Both GFP-AR and untagged AR demonstrated similar
nucleartranslocation responses(SupplementaryFig.S2A)with GFP-
AR achieving.90% of the untagged AR response at similar
concentrations (EC50GFP=0.4260.05 nM, EC50untagged=
2.1160.50 nM). When the hyperspeckling response is examined
(Supplementary Fig. S2B), responses are again at similar concentra-
tions (EC50GFP=1.2160.28 nM, EC50untagged=4.2660.54 nM),
with GFP-AR reaching .55% of the maximal untagged AR
response. The transcriptional reporter gene activity response
(Supplementary Fig. S2C) is similar to hyperspeckling where
GFP-AR achieves ,50% of the maximal untagged AR
response at similar concentrations (EC50GFP=0.9060.29 nM,
EC50untagged=1.7460.24 nM). In allcomparisons, the EC50 values
were similar between tagged and untagged AR suggesting that the
addition of the GFP tag does not significantly interfere with the
C-terminal ligand binding domain.
The ability to perform cell-by-cell analysis allowed us to test the
hypothesis that expression level alters the observed responses. At
higher levels of expression, an increased magnitude of hyperspeck-
ling was observed with no effect on nuclear translocation (Fig. 5A
and 5B). At these higher levels of AR expression (elevated by 2- to
4-fold), transcriptional reporter gene activity was repressed
significantly despite the elevated hyperspeckling (Fig. 5C), and
completely abolished as expression levels increased. These
measurements were taken from cells transiently transfected with
GFP-AR in order to poll a range of AR expression beyond that
observed in our HeLa stable cell lines. These results suggest that
the reason why we are able to achieve high assay quality is largely
due to the ability to examine a narrow range of AR expression that
is essentially free from potential over-expression artifacts.
HTM Analysis of AR Functions
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treatment, we also quantified responses after a brief pulse of the
agonist R1881. Surprisingly, after the HeLa GFP-AR cells were
exposed to a 2 hr pulse of 1 nM R1881, the intracellular
distribution of AR remained nuclear for up to 15 hr after
treatment (Supplementary Fig. S3A). During this time, new
protein synthesis was inhibited using cyclohexamide. To ensure
the result was not due to residual ligand in the media, we tested the
media removed after 15 hrs and were not able to induce the
observed response in fresh cells (data not shown). We next reduced
the exposure time to either 0.5 hr or 1 hr and again observed
nuclear retention of AR (Supplementary Fig. S3A). In contrast,
when we examined the nuclear hyperspeckling response after the
2 hr pulse of R1881, the hyperspeckling peaked but then
decreased over time (Supplementary Fig. S3A). The nuclear
retention is not due to the GFP fusion as we saw similar results
when we transiently introduced untagged AR into HeLa cells
(Supplementary Fig. S3A).
Figure 4. Dose dependent effects measured in panel of steroid compounds. The differential effects of various steroidal compounds on AR
nuclear translocation, nuclear hyperspeckling, and transcriptional reporter gene activity in HeLa GFP-AR. Cells transfected with pARR-2PB-dsRED2skl
reporter vector and maintained in 5% SD-FBS media for 12 hr. Cells were treated with indicated compound for 18 hr in 5%SD-FBS. Results normalized
to negative (no treatment) and positive (R1881) controls. Tested compounds include known AR agonist R1881 (A), mibolerone (B), and DHT(C)a s
well as other steroidal compounds estradiol (D), progesterone (E) and corticosterone (F). EC50 values calculated using SigmaPlot 4-parameter curve
fitting tool and presented6std. error (G). Data represents average of 8 experiments.
doi:10.1371/journal.pone.0003605.g004
HTM Analysis of AR Functions
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to shuttle between the cytoplasm and the nucleus after ligand
withdrawal, we used a live cell fluorescence loss in photobleaching
(FLIP) assay. The principle of the assay is that if reiterative
photobleaching in the cytoplasm results in loss of nuclear
fluorescence, the fluorescent protein must be able to shuttle from
the nucleus into the cytoplasm. We transfected HeLa GFP-AR
cells with a plasmid encoding hcRED (a 25 kDa-red fluorescent
protein) to allow visualization of the cytoplasmic region (Supple-
mentary Fig. S3C) and examined cells before ligand treatment and
after 5 hours of ligand withdrawal. We observed a rapid loss of
nuclear fluorescence with hcRED, consistent with a small protein
able to rapidly shuttle between cellular compartments (Supple-
mentary Fig. S3B–C). We also observed a slower, but persistent
loss of GFP-AR nuclear intensity in both the untreated, treated,
and ligand withdrawn HeLa GFP (Supplementary Fig. S3B–C).
The time required for loss of one half of the original nuclear
fluorescence was, on average, 1565 sec (n=21) for hcRED,
114618.1 sec (n=11) for untreated GFP-AR, 612651.9 sec
(n=11) for treated GFP-AR and 559643.2 sec (n=10) for ligand
withdrawn GFP-AR. These results are consistent with continued
AR shuttling between the nucleus and cytoplasm after ligand
withdrawal and with previous heterokaryon assays [31]. These
data suggest the presence of post-translational modification(s) and/
or long-lasting interactions in the nucleus sufficient to retain AR,
also sufficient to cause continued nuclear import of the receptor,
but not sufficient to maintain the hyperspeckled pattern. Further,
these findings again demonstrate that nuclear translocation and
hyperspeckling are distinct biological steps.
WealsoexaminedtheARresponsetoothersteroidhormonessuch
as estradiol (E2), progesterone (PRO), estrone (EST), corticosterone,
and androstenedione. Consistent with previously published cytolog-
ical and transcriptional results, our single cell analyses revealed that
while EC50 values were significantly different, at high concentrations
of these steroids, maximal effects rivaled known agonists (Fig. 4,
Supplementary Table S6). Interestingly, the ,30-fold increased
sensitivity of agonists for nuclear translocation vs. hyperspeckling and
transcription were not observed with these steroids.
Figure 5. Changes in AR expression level can alter magnitude of responses, but not the concentration at which they occur. To
generate a population of cells with a wide range of expression levels, HeLa cells were transiently transfected with GFP-AR and the pARR-2PB-
dsRED2skl construct and treated for 18 hr with a R1881 titration. Cells were fixed, DAPI stained, and imaged using the IC100 HTM. Because of image
artifacts generated due to the range of expression observed with transient transfections, images were analyzed using Pipeline Pilot software package.
After cells were analyzed, the population was subdivided into low, medium low, medium high, and high based on total GFP-AR expression. A. Dose
response curves for nuclear translocation failed to demonstrate any affects on the response by AR expression level. B. Dose response curves for
nuclear hyperspeckling demonstrated that medium-high and high AR expression was associated with increased amount of hyperspeckling; however,
the calculated EC50 values were not significantly different between the populations. C. Analysis of cells treated with 100 nM R1881 demonstrates
that transcriptional reporter gene activity in cells with medium-high to high levels of AR expression was significantly (p,0.001) reduced despite
increased hyperspeckling.
doi:10.1371/journal.pone.0003605.g005
HTM Analysis of AR Functions
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Transcriptional Reporter Gene Activity and
Hyperspeckling
We and others have qualitatively shown that the anti-androgens
o-hydroxyflutamide (OHF) and bicalutamide (CAS) can induce
AR nuclear translocation, but not the hyperspeckling induced by
AR agonists [1–3,32,33]. To quantitatively confirm these results
with our assay system, we tested OHF, CAS and nilutamide (NIL)
alone. The three compounds induced nuclear translocation at high
concentrations, having EC50 values ,600-fold higher than R1881
and maximum responses 70%–80% of R1881 (Fig. 6, Supple-
mentary Table S6). As expected for these antagonists, no
significant hyperspeckling or induction of transcription was
observed.
To characterize the potential antagonistic responses, each test
compound was added to the cells approximately 15 minutes
before adding 10 nM R1881. As expected, a significant dose-
Figure 6. Dose dependent effects measured in panel of AR antagonist compounds. The differential effects of various antagonist
compounds on AR nuclear translocation, nuclear hyperspeckling, and transcriptional reporter gene activity in HeLa GFP-AR are plotted. Cells
transfected with pARR-2PB-dsRED2skl reporter vector and maintained in 5% SD-FBS media for 12 hr. Cells were treated with indicated compound
either alone (A, B, C) or with 10 nM R1881 (D, E, F) for 18 hr in 5%SD-FBS. Results normalized to negative (no treatment) and positive (R1881)
controls. When possible, EC50 values were calculated using SigmaPlot 4-parameter curve fitting tool and presented6std. error (G). Data represents
average of 8 experiments.
doi:10.1371/journal.pone.0003605.g006
HTM Analysis of AR Functions
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observed, causing a 71–85% decrease in the dsRED2skl reporter
signal (Fig. 6, Supplementary Table S7). Calculated transcriptional
repression IC50 values for OHF, CAS and NIL were 677.1619.2,
645.1617.1, and 718631.9 nM. While our calculated IC50
values for CAS after 24 hours are a few fold higher than other
cell-based assays (e.g., luciferase) performed at 48–72 hrs, these
population-based readouts will also be highly dependent on the
actual concentrations of R1881 used for the competition [28]. By
examining the other measurements collected, we determined that
effects upon transcriptional reporter gene activity were linked to a
significant reduction in the ability of AR to develop an agonist-
induced hyperspeckled nuclear pattern (81–90%, Fig. 6, Supple-
mentary Table S7).
To further understand the range of responses of AR trafficking
and function potential mechanisms, we examined several environ-
mental compounds previously characterized as having anti-andro-
genic activity. These compounds included Vinclozolin (VNZ; [34]),
nitrofen (NF; [2]), and DDT [35], When tested alone, none were
able to induce a detectable increase in transcriptional reporter gene
activity, despite that fact that all induced modest nuclear
translocation of the receptor (45–53% of R1881 response) at high
concentrations(EC50 ,848to 911 nM). Mechanistically,the lackof
a transcriptional reporter gene activity response is also linked to the
inability of these compounds to induce a strong hyperspeckling
response (Fig. 6, Supplementary Table S6). When incubated with
10 nMR1881,allthreecompoundsreducedtranscriptionalreporter
gene activity (49–55%) with response patterns similar to those
observed with CAS, OHF, and NIL (Supplementary Table S7).
These results suggest the mechanisms by which these environmental
compounds exert their effects may be similar to those observed with
the known antagonists OHF, CAS, and NIL.
We also screened a small panel of novel compounds thought to
interact with AR. While a majority of these compounds did show a
response in terms of transcriptional reporter gene activity (data not
shown), the compound Decursin demonstrated a unique response
pattern. When observed in combination with 10 nM R1881
(Fig. 6, Supplementary Table S7), the compound caused an
antagonistic response (45% decrease in AR transcriptional
reporter gene activity, EC50=132006152 nM). Surprisingly,
however, there was a decrease in R1881-induced nuclear
translocation (95%, EC50=122906430 nM); further, he small
nuclear pool also exhibited a loss of hyperspeckling (94% in
NVAR, EC50=105836865 nM). These results are consistent with
previous biochemical studies and demonstrate the utility of the
single cell assay to identify and characterize novel cellular
responses based on both cytological and functional readouts [36].
Response to Additional Compounds
To further explore the utility of our assay, we examined
compounds (Atrazine, ATZ; Octophenol, OCT; diethylstilbestrol,
DES) that exhibit estrogenic activity, but have rather consistently
been reported to lack androgenic activity [28]. These compounds
did not yield a significant response on any of the three parameters
measured alone or with 10 nM R1881 (Supplementary Table S6
and S7). These results again demonstrated the specificity of the
assay and, importantly, suggest that the effects of these compounds
are not derived in significant measure from an androgenic or anti-
androgenic mechanism.
Relationship between Cell Cycle and Observed
Responses
To emphasize the multiplex nature of this assay further, we
examined the relationship between the cell cycle and cellular
responses observed with R1881, OHF, and thymidine. To perform
these studies, we simplified the HCS cell cycle analysis techniques
described by Gesparri et al. [37] to a DNA content (DAPI)/EdU
incorporation biparametric analysis to identify G1, S phase, and G2
cells in unsynchronized growing cells (Fig. 6A). Cells were prepared
as normal except with a brief 30 minute exposure to 10 mME d U ,
which will incorporate into newly synthesized DNA similar to BrdU,
prior to fixation. During image analysis, total nuclear DAPI signal
(DNA) and mean nuclear EdU signal from each cell was quantified
and used to determine cell cycle.
As expected, thymidine demonstrated a dose-dependent ability
to block HeLa GFP-AR cells in G1 (EC50=2.6 mM60.2 mM)
and significantly reduced the occurrence of cells in S-phase
(42.6%R0.5%, EC50=1.3060.01 mM, p,0.01: Fig. 7A–B).
Treatment of cells with R1881 also results in a dose dependent
growth arrest of cells characterized by a G1/S block
(EC50=0.1060.03 nM) and concomitantly a significant reduc-
tion in S-phase cells (42.6%R0.7%, EC50=0.0760.02 nM,
p,0.01) (Fig. 7A–B). This response is similar to cell cycle effects
of AR when is re-introduced to the PC3 prostate cancer cell line
[38]; OHF did not have any appreciable effect on the cell cycle.
By defining the cell cycle position on a cell-by-cell basis, we next
determined cell responsiveness to compounds. In untreated cells, G2
cells have a significantly higher percentage of the receptor in the
nucleus (data not shown). With an R1881 titration, this pattern
persists with G2 cells having 8–12% more AR in the nucleus
compared to G1 cells(p,0.05; Fig. 7C). A similar difference is
observed with OHF (Fig. 6C). In comparison, there is no significant
deference between G1, G2, and S phase cells AR nuclear
hyperspeckling in untreated cells (data not shown). In response to
R1881, G2 cells have 2.1-fold greater nuclear hyperspeckling
response than G1 cells (p,0.01; Fig. 7D). In contrast, S phase cells
had a 2.3-fold reduction in the amount of nuclear hyperspeckling
compared to G1 cells (p,0.01; Fig. 7D). Cell cycle effects on AR
transcriptional reporter gene activity could not be determined due to
the reporter accumulation occurring over 18 hrs, during which the
cells may continue to progress through the cell cycle. In general,
these results show how the AR response is affected by the cell cycle
and provide increased accuracy and insight to previous studies
examining the relationship between AR transcriptional reporter
gene activity and the cell cycle.
Altered Ligand Responses Observed with T877A
(Prostate Cancer) and F764L (AIS) Mutations
Having determined both the agonist and antagonist responses in
the assay with wild type AR, we next wanted to examine the assay
performance with an AR mutant relevant to prostate cancer. The
well-studied T877A mutation, found in the LNCaP cell line,
effectively relaxes the stringency of the ligand binding pocket
allowing the receptor to become ‘‘promiscuous’’ and respond to a
variety of additional ligands [13,39]. When tested with each
compound alone, the effects of the T877A mutation can clearly be
seen. Whereas the agonists R1881, mibolerone, and DHT gave
results within 1% of that observed with WT-AR, estradiol and
progesterone agonist activity increased approximately 300% in all
measurements (Supplementary Fig. S4, Supplementary Table S6
and S7). In addition, OHF’s potency at inducing nuclear
translocation of T877A dramatically increased nearly 100-fold.
Further, a 7.5-fold increase in hyperspeckling was observed
(EC50=125.9614.1 nM). The same pattern was observed with
transcriptional reporter gene activity with a maximal effectincreased
by 42.5 fold in cells expressing the T877A mutant. These results
confirm the agonist response associated with T877A to OHF [13].
The ability to rapidly determine how a mutation affects ligand
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mutations increases in metastatic prostate cancer [40].
Parallel to studying mutations associated with prostate cancer,
we were also interested in characterizing the inactivating
mutations associated with androgen insensitivity syndrome. In
particular, we sought in compounds that are able to induce a
normal response from the mutant receptor. The F764L mutation
was isolated from a patient with complete AIS and was previously
characterized as having an abnormally high ligand dissociation
rate [21]. After generating a HeLa GFP-AR F764L stable cell line,
we examined the responses of the mutation when cells were
treated with DHT, R1881, and mibolerone at concentrations
ranging between 200 nM to 0.02 nM. Consistent with the disease
phenotype, DHT failed to induce a strong hyperspeckling or
transcriptional reporter gene response even at the highest
concentrations tested (Fig. 8 A–C). DHT was able to induce
nuclear translocation of the mutant receptor, but only at a high
concentration (EC50=66.167.4 nM). In contrast, when the cells
were treated with either R1881 or mibolerone, a marked response
was observed in all three parameters examined (Fig. 8 A–C). For
R1881, the maximal responses ranged between 40–60% of that
observed with the WT AR, but occurred at higher concentrations
(EC50 range=10.6–159.4 nM). Strikingly, higher concentrations
of mibolerone were able to induce maximal responses between 85–
105% of that observed with the WT receptor (EC50 range=2.6–
71.6 nM). These results not only demonstrate why the disease
phenotype is present (e.g., no response to endogenous DHT), but
also establishes a rapid and specific ability to identify therapeu-
tically-relevant compounds that may rescue receptor function.
Discussion
AR develops and maintains the male sexual phenotype under
physiologic conditions, and abnormalities in AR function
participate in the etiology of several diseases. In the ,20 years
that followed the molecular cloning of AR [41–43], biochemical
and molecular assays of this molecule have generated a plethora of
new information, resulting in an in-depth understanding of AR
function, including its involvement in regulating transcription and
identification of interacting proteins. Despite these important
advances, a simple, rapid, efficient and reproducible model to
study mechanisms of AR function remains elusive; numerous
separate biochemical techniques are still mandatory to facilitate
any hope of interpolation that may provide a systems biology level
appreciation of mechanisms. Furthermore, we have not been able
to significantly translate any mechanistic advances since AR
Figure 7. Analysis of the relationship between observed responses, and cell cycle in asynchronous HeLa GFP-AR cells treated with
R1881 (green square), o-hydroxyflutamide (red triangle), or thymidine (yellow diamond). A. Biparametric dot-plot analysis of total DNA
content (total DAPI signal per nucleus) and 5-ethynyl-29-deoxyuridine (EdU) incorporation. Dotted lines represent thresholds used to divide cells with
either low or high DNA content (vertical line) or cells positivelystainedfor EdU (horizontal line). Thepercent of cells in eachquadrant with each treatment
arerepresentedintheassociatedtable.B.Concentration-responsecurvesofthepercentofcellsinSphase(largemarkers)andG1/G2ratio(smallmarkers)
after an 18 hr treatment. C and D. Concentration-response curves examining nuclear translocation response (C) and nuclear hyperspeckling (D) in G1, S
phase, and G2 cells treated with R1881 and o-hydroxyflutamide. Results normalized to positive and negative controls (all cells).
doi:10.1371/journal.pone.0003605.g007
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ADI prostate cancer. This paper describes the characterization of
AR as it becomes transcriptionally activated after addition of
agonists, or repressed, after addition of antagonists, using an image
based technique that is highly amendable to large-scale screening
to identify effectors of AR function, and can serve as a framework
to study other nuclear receptors and transcriptional regulators.
The work described here is advantageous over previous cell
based assays in several ways and has provided useful insights on
AR biology. First, this assay generates multiplex high throughput
data that not only measures AR transcriptional reporter gene
activity, but also two other upstream steps linked to transcriptional
competence (nuclear translocation and hyperspeckling). By having
the ability to compare how compounds affect each of the
measurements, we were not only able to reiterate that compounds
such as R1881 are powerful AR agonists, but also that formation
of the hyperspeckled pattern associated with agonist bound
nuclear receptors is a distinct mechanistic step from nuclear
translocation and occurs only at ,30-fold higher agonist
concentrations. The correlation between formation of the
hyperspeckled pattern and transcriptional reporter gene activity
lends further support to the concept that this pattern represents an
increased trend toward protein complex formation and transcrip-
tional regulation. A similar link between hyperspeckling of other
Type I nuclear receptors has been reported (e.g., ER, PR, GR).
While the speckles themselves appear to be only randomly
associated with sites of transcription, and are demonstrated to be
transient in the living cell by photobleaching methods, the degree
of AR-AR or AR-coregulator interactions determined by FRET
suggest they represent complexes at an ill-defined level of
maturation (relevant to activation potential). Alternately, the
speckles simply represent the notion that the vast majority of
complexes can form away from the very small portion of the
nuclear volume that contains target genes. If the latter case were
true, an underlying deterministic or stochastic mechanism(s) for
AR dynamics would be necessary to facilitate a means for the
complexes to find target genes.
We were also able to quantitatively confirm that traditional AR
antagonist (OHF, CAS, NIL) are able to induce nuclear
translocation fail at forming a hyperspeckled pattern; furthermore,
in the presence of agonist, transcription inhibition is linked to
blocking the formation of the hyperspeckled pattern. The
differences in the amount of speckling observed following exposure
to the various compounds used could reflect differences in the
identity of the recruited coregulators and/or the strength of AR-
CoR binding [44].
Figure 8. Differential responses of the F764L AR mutation to a panel of agonist. The effects of the F764L mutation on AR nuclear
translocation (A), nuclear hyperspeckling (B), and transcriptional reporter gene activity (C) in HeLa cells with treated with R1881 (red), mibolerone
(black), or DHT (green). Cells stably expressing F764L form of AR were transfected with pARR-2PB-dsRED2skl reporter vector and maintained in 5%
SD-FBS media for 12 hr. Cells were treated with indicated compound for 18 hr in 5%SD-FBS. When possible, EC50 values were calculated using
SigmaPlot 4-parameter curve fitting tool and presented6std. error. Data represents average of 4 experiments.
doi:10.1371/journal.pone.0003605.g008
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group known as ‘‘endocrine or environmental disruptors,’’ electing
to test agents with known ER or AR antagonistic activity. No
induction of AR transcriptional reporter gene activity was detected
with our small set of these substances, although both ER (at mM
concentration) and AR (at sub mM concentrations) disruptors
showed the ability to induce nuclear translocation and some minor
hyperspeckling. That these compounds have some affect on two of
the three agonist actions (translocation and hyperspeckling) may
indicate a mechanistic action unlike the known antagonists. While
failing to activate the probasin reporter, the moderate hyperspeck-
ling observed may indicate transcriptional effects on other genes.
Panels of AR sensitive transcriptional reporter genes and multi-
color mRNA fluorescent in situ hybridization (FISH) experiments
are in development to directly test this important question. In the
R1881 competition assay, no AR antagonistic activity was
detected for the ER disruptors; in contrast, the AR disruptors
DDT, Vinclozolin and Nitrofen were effective in preventing
hyperspeckling and transcriptional reporter gene activity at
concentrations very similar (,1.5-fold higher) to established AR
antagonists (OHF, Casodex and Nilutamide). The presence of
these substances in certain environments, and their recognized AR
antagonistic activity at concentrations that may be achieved after
chronic exposure is important, and according to some investigators
may affect AR-mediated functions such as spermatogenesis
[45,46] and testicular development [47]. Utilization of the HTM
multiplex AR assay could greatly assist in evaluating potential
endocrine disruptor effects on AR functions, cell cycle and toxicity;
further, this approach his highly amenable to all other gene
regulators, thus greatly expanding the ability to carefully monitor
xenobiotic effectors.
The second advantage of our approach is that the microscopic
nature of the assay permits the selection of individual healthy
interphase cells expressing near endogenous levels of AR. This is
an essential methodological characteristic because several critical
functions of a nuclear receptor are affected when it is over-
expressed, even if only to modestly higher levels [3,16]. This
suggests that bulk population-derived data, where the amount of
expressed exogenous protein is not controlled, must be carefully
interpreted to avoid confusing normal physiology with patholog-
ical expression levels that turn on the cell stress program ([48];
manuscript in preparation). In the work presented here, the ability
to closely select the expression level also allowed us to determine
that receptor expression levels (within the range examined here) do
not markedly affect nuclear translocation or hyperspeckling
sensitivity (as determined by EC50 values), but, rather, do
markedly affect the magnitude of the hyperspeckling and the
transcriptional reporter gene activity responses. The ability to
specifically link expression levels to multiple cellular responses will
be an important means to examine the functional significance of
altered protein expression levels sometimes observed in diseases
where AR is moderately over-expressed, such advanced metastatic
prostate cancer [49]. Furthermore, as some proteins and/or cells
appear to respond variably to over expression levels, access to
single cell data linking transcription factor levels to function is
fundamental to improved mechanistic understandings.
Along with the ability to correlate responses to expression level,
we were also able to link measurements to cell cycle subpopula-
tions. Our results demonstrate that in S-phase and G2 cells, AR is
significantly more nuclear than in G1 cells. With agonist
treatment, the increased nuclear localization in G2 is associated
with heightened nuclear hyperspeckling. In contrast, the S-phase
cells demonstrate decreased hyperspeckling with agonist treat-
ment. Although not directly studied here due to technical
limitations, these results would predict AR to have the highest
transcriptional reporter gene activity in G2 (increased nuclear
translocation and hyperspeckling). However, others have found
AR to have the highest transcriptional reporter gene activity in G0
and S phase [17]. The causes for this discrepancy could include,
but are not limited to, the use of different cell lines, potential
artifacts from chemically-based synchronization, or a regional,
physical disassociation of hyperspeckling and transcriptional
reporter gene activity during DNA synthesis. Utilization of a
short-lived fluorescent reporter protein or mRNA FISH of
endogenous target genes will be required to bring an improved
dynamic readout of gene expression into the multiplex analyses.
Finally, the flexibility of the assay allowed us to examine disease-
related AR mutations for altered compound responses. Especially
important would be the analysis of AR mutations thought to be
involved in prostate cancer treatment resistance [49] or AR
mutations involved in the androgen resistance observed in AIS.
The observation that hydroxyflutamide acted as an agonist on the
T877A mutation is in agreement with previous reports in COS
cells [13], and it is significant because this effect was observed at a
concentration of 75–85 nM, a readily achieved level in patients
treated with this compound. Interestingly, and in agreement with
known literature, lower doses of estradiol and progesterone
showed the ability to activate the T877A AR mutant. Whether
this observation has clinical implications is doubtful. Concentra-
tions of 50–60 nM would still be necessary for these two ligands to
activate AR, and these levels are clearly supraphysiologic and not
likely achievable in normal individuals, or in patients with prostate
cancer receiving hormonal manipulation. For the F764L mutation
associated with AIS, it is significant that we were able to observe
an increased response with the synthetic androgen R1881 and
mibolerone. Because HeLa cells do not express the enzymes
necessary to metabolize DHT, the increased responses observed
with R1881 and mibolerone are due to characteristics of the
ligands, and not higher intracellular concentrations than DHT.
The ability to rapidly identify ligands that activate a mutant
receptor lends itself to the concept of personalized medicine for
AIS patients. To this end, application of our multiplex HTM
approach is underway with patient-derived genital skin fibroblasts
(Szafran, Mancini and Marcelli, unpublished observations).
Overall, the technology described in this paper represents a
significant advance that builds upon our previous efforts to study AR
at the single cell level by now allowing a quantitative assessment of
multiple aspects of intracellular AR function. The technology is
straightforward,reliable, reproducible,and is automated to the point
where large libraries of compounds can now be tested to identify
novel AR agonists and antagonist, including endocrine disruptors.
Moreover, use of ARs harboring patient-related mutations will be
amenable to agonist/antagonist screening for personalized patient
drug selection. Finally, combined with current RNAi technologies,
this multiplex HTM assay should also aid in the identification of
proteins involved in pathways that regulate AR biology (Szafran,
Marcelli and Mancini, in preparation).
Methods
Reagents
All chemicals were obtained from Sigma-Aldrich (St. Lois, MO)
unless stated otherwise. Methyltrienolone (R1881) was obtained
from NEN Life Science Products (Boston, MA).
Generation of Stable Cell Lines
Stable HeLa cell lines expressing GFP-AR (wild type and
T887A) were generated to ensure GFP-AR protein was expressed
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1 mg/well plasmid DNA and 0.01 mg/well linear hygromycin
marker (BD) using BioRad Transfectin reagent 1 day after plating
in six-well plates. After 24 hours, cells were trypsinized and plated
in medium supplemented with 500 mg/ml Hygromycin (Sigma, St
Louis, MO) in 10 cm tissue culture dishes. Clones were selected
and checked for appropriate GFP-AR distribution and expression
by widefield fluorescent microscopy and western blotting. Stable
cell lines were maintained in DMEM/F12 medium supplemented
with 5%FBS and 500 mg/ml hygromycin.
High Throughput Microscopy – Sample Preparation
Twenty-four hours before transfection, cells were plated onto
100 mm plastic dishes in medium supplemented with charcoal
stripped and dialyzed FBS (SD-FBS). Transient introduction of the
pARR-2PB-dsRED2skl reporter construct was performed using
6.0 mg reporter plasmid and 6.0 mgc a r r i e rD N A( B l u e S c r i p t ,
Stratagene, San Diego, CA) using Transfectin following standard
protocols. After 8 hour incubation, DNA/lipid complexes were
removed. Cells were then trypsinized and replated at 8500 cells per
well in Matrical 384 poly-D-lysine treated 384 well optical glass
bottom plates and incubated an additional 12 hours to allow for cell
adhesion. Cells were then exposed to for 24 h to ligands at
concentrations ranging from 10
25 Mt o1 0
214 M. Compound
dilutionsandfinaladdition to multi-well plates wereperformedusing
a Beckman Biomek NX robotic platform to ensure repeatability
from experiment to experiment. For competition studies, after
experimental compounds were added to the cells, the competitor
(10 nM R1881) was added to the wells approximately 15 minutes
later. After incubation was complete, using the Biomek NX robot,
plates were washed with PBS and fixed for 20 min at RT in 4%
formaldehyde prepared in CSK buffer (80 mM potassium PIPES,
pH 6.8, 5 mM EGTA, 2 mM MgCl2). After fixation, cells were
briefly permeabilized (5 min) with 0.5% Triton-X and prepared for
imaging by washing in PBS, aspirating the washed solution, and
adding a 1 ng/ml DAPI solution. Cells were imaged in PBS.
For experiments in which cell cycle effects were determined,
cells were labeled using an Invitrogen Click-iT cell cycle analysis
kit using supplied protocols. Prior to fixation, cells were exposed to
10 mM EdU for 30 minutes. Cells with EdU incorporation were
labeled by an EdU specific antibody conjugated to an A647
florescent marker. Because the Click-iT labeling decreases GFP
signal intensity, AR was labeled using an Anti-AR antibody (Dr.
Nancy Weigel) and A488 secondary antibody (Molecular Probes).
High Throughput Microscopy – Imaging
Cells were imaged using the Cell Lab IC-100 Image Cytometer
(IC100; Beckman Coulter) platform which consists of 1.) Nikon
Eclipse TE2000-U Inverted Microscope (Nikon; Melville, NY) 2.)
Chroma 82000 triple band filter set (Chroma; Brattleboro, VT) 3.)
An imaging camera: Hamamatsu ORCA-ER Digital CCD camera
(Hamamatsu; Bridgewater, NJ) and 4.) A focusing camera:
Photoonics COHU Progressive scan camera (Photonics; Oxford,
MA). The microscope was equipped with a Nikon S Fluor 406/
0.90NAobjectiveand theimagingcameraset tocapture8bitimages
at161binning(134461024pixels;6.5 mm2pixelsize)with4images
captured per field (DAPI, GFP/A488, dsRED2skl, A647). In
general, 49 images were captured per well for image analysis.
High Throughput Microscopy – Image Analysis
Images were analyzed using either Cytoshop Version 2.1
(Beckman Coulter) or Pipeline Pilot Version 6.1.5 (Scitegic) analysis
software. Nuclear masks were generated by applying a non-linear
least-squares image filter combined with automatic histogram based
thresholding. General background signal in the GFP channel was
corrected by automatic mean background subtraction. Total area of
GFP-AR image extraction was determined by intersection of a
chosen extraction radius (approximately 25% larger than average
nucleus radius) and a Voroni tessellation polygon. Cell populations
were filtered to achieve a uniform population of cells without cell
aggregates, mitotic cells, apoptotic cells, and cellular debris. Applied
gates were based upon 1.) nuclear area 2.) nuclear wiggle (AREA/
PERIMETER) 3.) DNA content (DAPI INTENSITY). AR
cytoplasm to nuclear translocation, AR nuclear variation/hyper-
speckling,and transcriptionalreportergeneactivityweredetermined
using algorithms within the image analysis software (Fraction
Localized In Nucleus (FLIN), Nuclear Variation (NVAR), and total
channel 2 intensity (CORR2)). For cell cycle analysis, two additional
parameters were collected; total channel 0 nuclear intensity
(TOTAL_NUC_DAPI) and average channel 3 nuclear intensity
(AVG_NUC_Ch03). All data was exported to Pipeline Pilot and
responses were normalized to a 0 to 1 range based on (2)a n d( +)
controls and quadruplicates averaged. EC50 values were calculated
by plotting a simple scatter plot of response vs. ligand concentration
and using SigmaPlot four parameter logistic curve fitting algorithm.
Due to the nature of the curve fitting algorithm, for those responses
that did not plateau the response observed at the highest
concentration was assumed maximal.
Live Cell Microscopy - FLIP
For live cell FLIP experiments, HeLa GFP-AR cells grown on
23 mm glass bottom Delta T dishes (Bioptechs), transfected with
0.4 mg of pCMV-hcRED plasmid plus 0.8 mg of carrier DNA
using Transfectin (BioRad), and allowed to recovery for 24 hrs
before being placed onto a LSM 510 confocal microscope (Carl
Zeiss, Thornwood NY) equipped with a 636(NA 1.4) objective.
Cells were maintained at 37uC using a Bioptechs Delta Controller
and fresh media containing the appropriate ligand was cycled over
the cells. A single Z-section was imaged before and at time
intervals following each bleach. The bleach was performed using
the laser set 488 nm for GFP at maximum power for 10 iterations
(,1 sec) in a circular region contained within the cytoplasm of the
cell. Bleaches were repeated every 10 seconds for the duration of
the experiment (700 s) Fluorescent intensities of regions of interest
were determined using LSM software and data was exported to
Excel (Microsoft, Inc.) to normalize intensity to the pre-bleach
image. LSM images were exported as TIF files and final figures
were generated using Adobe Photoshop.
Statistical Analysis
Overall assay quality was determined using the Z’ calculation, a
dimensionlessmeasurement determined using the following equation:
Z’~1{
3szcontrolz3s{control ðÞ
mzcontrol{m{control
       
where s represents the standard deviation of both positive (R1881)
and negative control (non-treated) and m represents the mean of the
populations. A Z’ value of 1 is the theoretical ‘‘perfect’’ assay and
values between 0.2 and 0.6 are typical for cell based assays.
To predict the number of cells needed per well to achieve
significant results, we applied a derivation of the Devore equation
previously described. Briefly, the Devore equation:
N~2
za{zb
  
sÞ
DmMSR
   2
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dynamic range of the measurement, and za and zb relate to type 1
and type 2 errors was used to construct a plot that represents the
number of cells needed for the desired minimum significant
response. For the assay described here, acceptable type 1 and type
2 errors were set at 0.01 and 0.20 (results presented in
Supplementary Table S5).
Determination of significant differences between compounds
was accomplished by first performing an ANOVA analysis
followed by a post-hoc multiple comparison analysis with
significance set at ,0.05.
Supporting Information
Figure S1 Variation between titration curves in the AR agonist,
single plate. Three 96 well plates were prepared with HeLa GFP-
AR cells transfected with the pARR-2PB reporter construct.
Multiple rows were treated with a serial dilution of R1881 ranging
from 1026 M to 10211 M. In the agonist assay, at low
concentrations (far right points) of R1881, (A) nuclear transloca-
tion (FLIN), (B) nuclear speckling (NVAR), and (C) AR
transcriptional reporter gene activity (CORR2) are minimal. As
R1881 concentration increases, a dramatic increase in the
measurements is observed with saturation of response observed
at <100 nM. The color scale represents a range of response from
maximal (white) to minimal response (black) for each measure-
ment. All results shown are from a single plate of the set.
Found at: doi:10.1371/journal.pone.0003605.s001 (2.38 MB TIF)
Figure S2 GFP-AR responds in a similar manner to untagged
AR but with diminished maximal responses. HeLa cells were
transiently transfected with either untagged AR or GFP-AR
plasmids in addition to the pARR-2PB-dsRED reporter plasmid.
Twenty-four hours after transfection, cells were exposed to
multiple concentrations of DHT ranging from 0.002 nM to
200 nM for 18 hr. Cells were then fixed and probed with an anti-
AR antibody to visualize both GFP-tagged and untagged AR in
images captured by the automated IC100 microscope. Images
were analyzed using Pipeline Pilot software and the nuclear
translocation (A), nuclear hyperspeckling (B), and transcriptional
activity (C) responses quantified.
Found at: doi:10.1371/journal.pone.0003605.s002 (0.83 MB TIF)
Figure S3 GFP-AR retains a nuclear distribution with decreased
hyperspeckling but maintains the ability to shuttle into the
cytoplasm after agonist removal. A. HeLa GFP-AR cells were
treated with 1 nM for 30 min, 1 hr, or 2 hrs. After ligand
treatment, R1881 was removed by serial washes with ligand free
media containing cyclohexamide to prevent new protein synthesis.
Cells were then fixed, imaged, and examined for the localization of
the receptor at 3, 6, 9, 12, and 15 hrs using previously described
image analysis tools. Responses were normalized to untreated
controls and response seen with 1 nM R1881 treatment for 2 hrs.
An additional experiment using untagged AR was also performed
to ensure response was not due to the inclusion of the GFP tag on
the receptor. The ability of GFP-AR to shuttle between the
nuclear and cytoplasmic compartments during and after ligand
treatment was analyzed using the FLIP photobleaching technique
where a region in the cytoplasm is repeatedly bleached. B. A graph
comparing the rate at which nuclear GFP-AR fluorescence is lost
in the absence of ligand (untreated, t1/2=114618.1 sec, n=11),
in the presence of 10 nM R1881 (Treated, t1/2=612651.9 sec,
n=11), and after ligand withdrawal (Withdrawal, t1/
2=559643.2 sec, n=10). To ensure results were not due to
general photobleaching during imaging, cells were examined
where the targeted photobleaching region was outside of the
cellular area (Photobleach Control). Both R1881 treatment and
withdrawal significantly slow but does not stop the rate that the
receptor shuttles between the nucleus and the cytoplasm. C.
Selected images from FLIP experiment.
Found at: doi:10.1371/journal.pone.0003605.s003 (2.19 MB TIF)
Figure S4 Differential responses of the T877A AR mutation.
The differential effects of the T877A mutation on AR nuclear
translocation, nuclear hyperspeckling, and transcriptional reporter
gene activity in HeLa GFP-AR with selected compounds. Cells
stably expressing either WT (unhatched) or T877A (hatched)
forms of AR were transfected with pARR-2PB-dsRED2skl
reporter vector and maintained in 5% SD-FBS media for 12 hr.
Cells were treated with indicated compound either alone (grey
bars) or with 10 nM R1881 (white bars) for 18 hr in 5%SD-FBS.
Results normalized to negative (no treatment) and positive (R1881)
controls. When possible, EC50 values were calculated using
SigmaPlot 4-parameter curve fitting tool and presented6std.
error. Data represents average of 4 experiments.
Found at: doi:10.1371/journal.pone.0003605.s004 (1.51 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0003605.s005 (0.05 MB PDF)
Table S2
Found at: doi:10.1371/journal.pone.0003605.s006 (0.03 MB PDF)
Table S3
Found at: doi:10.1371/journal.pone.0003605.s007 (0.04 MB PDF)
Table S4
Found at: doi:10.1371/journal.pone.0003605.s008 (0.03 MB PDF)
Table S5
Found at: doi:10.1371/journal.pone.0003605.s009 (0.56 MB TIF)
Table S6
Found at: doi:10.1371/journal.pone.0003605.s010 (0.06 MB PDF)
Table S7
Found at: doi:10.1371/journal.pone.0003605.s011 (0.04 MB PDF)
Acknowledgments
The authors gratefully acknowledge longstanding support and advice on
high throughput microscopy, image analysis and reporting from Jeff Price
(Vala Sciences), Tim Moran, Robin Truelove and Leo Bleicher (Accelrys,
San Diego, CA). Environmental compound advice was kindly provided by
George Bittner (CertiChem, Austin, TX). The authors also greatly
appreciate the expert technical support from Jeannie Zhong, Kali Antalis,
Shihua Sun, and Maureen G. Mancini.
Author Contributions
Conceived and designed the experiments: ATS MM MAM. Performed the
experiments: ATS MS. Analyzed the data: ATS MS MM MAM.
Contributed reagents/materials/analysis tools: ATS MM MAM. Wrote
the paper: ATS MM MAM.
References
1. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee B, et al. (2000) Dynamics
of intracellular movement and nucleocytoplasmic recycling of the ligand-
activated androgen receptor in living cells. Mol Endocrinol 14(8): 1162–74.
2. Tomura A, Goto K, Morinaga H, Nomura M, Okabe T, et al. (2001) The
subnuclear three-dimensional image analysis of androgen receptor fused to green
fluorescence protein. J Biol Chem 276(30): 28395–401.
HTM Analysis of AR Functions
PLoS ONE | www.plosone.org 15 November 2008 | Volume 3 | Issue 11 | e36053. Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, et al. (2006)
Quantifying effects of ligands on androgen receptor nuclear translocation,
intranuclear dynamics, and solubility. J Cell Biochem 98(4): 770–88.
4. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, et al. (1995)
Androgen receptor defects: historical, clinical, and molecular perspectives.
Endocr Rev 16(3): 271–321.
5. Griffin JE, McPhaul MJ, Russel DW, Wilson JD (2001) The androgen resistance
syndromes: steroid 5a-reductase 2 deficiency, testicular feminization and related
disorders. In Scriver CR, et al., eds. The metabolic and molecular bases of
inherited diseases. New York: McGraw-Hill, pp. 4117–4146.
6. Marcelli M, Lamb DJ, Weigel NL, Cunningham GR (2003) Androgen signaling
in prostatic neoplasia and hyperplasia. In Bagatell C, Bremner WJ, eds.
Androgens in health and disease. Totowa: Humana Press, pp. 157–189.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics, 2006
CA Cancer J Clin 56(2): 106–30.
8. Feldman BJ, Feldman D (2001) The development of androgen-independent
prostate cancer. Nat Rev Cancer 1(1): 34–45.
9. Dehm SM, Tindall DJ (2005) Regulation of androgen receptor signaling in
prostate cancer. Expert Rev Anticancer Ther 5(1): 63–74.
10. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, et al. (1999) Selection for
androgen receptor mutations in prostate cancers treated with androgen
antagonist. Cancer Res 59(11): 2511–5.
11. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, et al. (2004) The
androgen axis in recurrent prostate cancer. Clin Cancer Res 10(2): 440–8.
12. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006)
Increased expression of genes converting adrenal androgens to testosterone in
androgen-independent prostate cancer. Cancer Res 66(5): 2815–25.
13. Veldscholdte J, Ris-Stalpers C, Kuiper GGJM, Jentser G, Berrevoets C, et al.
(1990) A mutation in the ligand binding domain of the androgen receptor of
LnCAP cells affects steroid binding characteristics and response to anti-
androgens. Biochem Biophys Res Commun 173: 534–540.
14. Berno V, Hinojos CA, Amazit L, Szafran AT, Mancini MA (2006) High-
resolution, high-throughput microscopy analyses of nuclear receptor and
coregulator function. Methods Enzymol 414: 188–210.
15. Sultan C, Balaguer P, Terouanne B, Georget V, Paris F, et al. (2001)
Environmental xenoestrogens, antiandrogens and disorders of male sexual
differentiation. Mol Cell Endocrinol 178(1–2): 99–105.
16. Hoeck W, Hofer P, Groner B (1992) Overexpression of the glucocorticoid
receptor represses transcription from hormone responsive and non-responsive
promoters. J Steroid Biochem Mol Biol 41(3–8): 283–9.
17. Narayanan R, Edwards DP, Weigel NL (2005) Human progesterone receptor
displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol
25(8): 2885–98.
18. Hu JM, Bodwell JE, Munck A (1994) Cell cycle-dependent glucocorticoid
receptor phosphorylation and activity. Mol Endocrinol 8(12): 1709–13.
19. Martinez ED, Danielsen M (2002) Loss of androgen receptor transcriptional
activity at the G(1)/S transition. J Biol Chem 277(33): 29719–29.
20. Lee S, Howell BJ (2006) High-content screening: emerging hardware and
software technologies. Methods Enzymol 414: 468–83.
21. Marcelli M, Zoppi S, Wilson CM, Griffin JE, McPhaul MJ (1994) Amino acid
substitutions in the hormone-binding domain of the human androgen receptor
alter the stability of the hormone receptor complex. J Clin Invest 94(4): 1642–50.
22. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, et al. (2007)
Compartmentalization of androgen receptor protein-protein interactions in
living cells. J Cell Biol 177(1): 63–72.
23. Metivier R, Reid G, Gannon F (2006) Transcription in four dimensions: nuclear
receptor-directed initiation of gene expression. EMBO Rep 7(2): 161–7.
24. Zhang JF, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite
probasin promoter confers high levels of prostate-specific gene expression
through regulation by androgens and glucocorticoids in vitro and in vivo.
Endocrinology 141(12): 4698–4710.
25. Morelock MM, Hunter EA, Moran TJ, Heynen S, Laris C, et al. (2005) Statistics
of assay validation in high throughput cell imaging of nuclear factor kappaB
nuclear translocation. Assay Drug Dev Technol 3(5): 483–99.
26. Korner W, Vinggaard AM, Terouanne B, Ma R, Wieloch C, et al. (2004)
Interlaboratory comparison of four in vitro assays for assessing androgenic and
antiandrogenic activity of environmental chemicals. Environ Health Perspect
112(6): 695–702.
27. Devore J (1995) Prabability and Statistics for Engineering and the Sciences. 4th
ed; Grove, CA: Brooks/Cole Publishing Co.
28. ICCVAM (2006) Addendum March 2006 to evaluation of in vitro test methods
for detecting endocrine disruptors, NIH Pub. 03-4503 of May, Editor.
29. Pirog EC, Collins DC (1999) Metabolism of dihydrotestosterone in human liver:
importance of 3alpha- and 3beta-hydroxysteroid dehydrogenase. J Clin
Endocrinol Metab 84(9): 3217–21.
30. Doering CH, Leyra PT (1984) Methyltrienolone (R1881) is not aromatized by
placental microsomes or rat hypothalamic homogenates. J Steroid Biochem
20(5): 1157–62.
31. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, et al. (2006) Stress kinase
signaling regulates androgen receptor phosphorylation, transcription, and
localization. Mol Endocrinol 20(3): 503–15.
32. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, et al. (1999)
Polyglutamine-expanded androgen receptors form aggregates that sequester heat
shock proteins, proteasome components and SRC-1, and are suppressed by the
HDJ-2 chaperone. Hum Mol Genet 8(5): 731–41.
33. Saitoh M, Takayanagi R, Goto K, Fukamizu A, Tomura A, et al. (2002) The
presence of both the amino- and carboxyl-terminal domains in the AR is
essential for the completion of a transcriptionally active form with coactivators
and intranuclear compartmentalization common to the steroid hormone
receptors: a three-dimensional imaging study. Mol Endocrinol 16(4): 694–706.
34. Wong C, Kelce WR, Sar M, Wilson EM (1995) Androgen receptor antagonist
versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide.
J Biol Chem 270(34): 19998–20003.
35. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, et al. (1995)
Persistent DDT metabolite p,p’-DDE is a potent androgen receptor antagonist.
Nature 375(6532): 581–5.
36. Guo J, Jiang C, Wang Z, Lee HJ, Hu H, et al. (2007) A novel class of
pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer
Ther 6(3): 907–17.
37. Gasparri F, Cappella P, Galvani A (2006) Multiparametric cell cycle analysis by
automated microscopy. J Biomol Screen 11(6): 586–98.
38. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, et al. (1993) Androgen-
induced inhibition of cell proliferation in an androgen-insensitive prostate cancer
cell line (PC-3) transfected with a human androgen receptor complementary
DNA. Cancer Res 53(6): 1304–11.
39. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, et al. (1980)
The LNCaP cell line–a new model for studies on human prostatic carcinoma.
Prog Clin Biol Res 37: 115–32.
40. Marcelli M, Ittmann M, Mariani M, land RS, Nigam R (2000) Androgen
Receptor Mutations in Prostate Cancer. Cancer Res 60: 944–949.
41. Tilley WD, Marcelli M, Wilson JD, McPhaul JM (1989) Characterization and
cloning of a cDNA encoding the human androgen receptor. Proc Natl Aca Sci
USA 86: 327–331.
42. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, et al. (1988)
Cloning of human androgen receptor complementary DNA and localization to
the X chromosome. Science 240(4850): 327–30.
43. Chang CS, Kokontis J, Liao ST (1988) Molecular cloning of human and rat
complementary DNA encoding androgen receptors. Science 240(4850): 324–6.
44. Kang Z, Janne OA, Palvimo JJ (2004) Coregulator recruitment and histone
modifications in transcriptional regulation by the androgen receptor. Mol
Endocrinol 18(11): 2633–48.
45. Lombardo F, Sgro P, Salacone P, Gilio B, Gandini L, et al. (2005) Androgens
and fertility. J Endocrinol Invest 28(3 Suppl): 51–5.
46. Anway MD, Memon MA, Uzumcu M, Skinner MK (2006) Transgenerational
effect of the endocrine disruptor vinclozolin on male spermatogenesis. J Androl
27(6): 868–79.
47. Uzumcu M, Suzuki H, Skinner MK (2004) Effect of the anti-androgenic
endocrine disruptor vinclozolin on embryonic testis cord formation and
postnatal testis development and function. Reprod Toxicol 18(6): 765–74.
48. Sharp ZD, Stenoien DL, Mancini MG, Ouspenski II, Mancini MA (2004)
Inactivating Pit-1 mutations alter subnuclear dynamics suggesting a protein
misfolding and nuclear stress response. J Cell Biochem 92(4): 664–78.
49. Pienta KJ, Smith DC (2005) Advances in prostate cancer chemotherapy: a new
era begins. CA Cancer J Clin 55(5): 300–18; quiz 323–5.
HTM Analysis of AR Functions
PLoS ONE | www.plosone.org 16 November 2008 | Volume 3 | Issue 11 | e3605